苯二氮卓类药物可增加COPD和PTSD患者的自杀风险

2018-10-14 MedSci MedSci原创

近期研究人员发现,在创伤后应激障碍(PTSD)或慢性阻塞性肺病(COPD)患者中长期使用苯二氮卓类药物可能会导致自杀风险增加。

苯二氮䓬类药物,又称苯二氮平,是一类精神药物,其核心化学结构是一个苯环和一个䓬环。第一种此类药物是氯氮䓬(利眠宁)。在1977年,苯二氮䓬类药物已是全球最高处方量的药物。苯二氮卓类药物是减少焦虑,催眠,抗惊厥和镇静药物,通常用于创伤后应激障碍或慢性阻塞性肺病,用药可以减轻症状,包括呼吸急促,焦虑,失眠。由于与药物相关的不良副作用包括COPD恶化和自身损伤的风险增加,苯二氮卓类药物的使用一直存在争议。

近期研究人员发现,在创伤后应激障碍(PTSD)或慢性阻塞性肺病(COPD)患者中长期使用苯二氮卓类药物可能会导致自杀风险增加。Lucas M. Donovan博士及其团队研究了在2010 - 2012年间接受医疗护理的44,555名退伍军人。在这些人中,23.6%的人长期服用苯二氮卓类药物(90天或更长时间)。研究人员发现长期使用苯二氮卓类药物治疗的COPDPTSD患者的自杀风险增加一倍以上。


原始出处:

https://www.europeanpharmaceuticalreview.com/news/80053/benzodiazepines-suicide/

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1776634, encodeId=032d1e7663435, content=<a href='/topic/show?id=457f8622190' target=_blank style='color:#2F92EE;'>#自杀风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86221, encryptionId=457f8622190, topicName=自杀风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65df38986519, createdName=Eleven24, createdTime=Fri Aug 09 00:30:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596828, encodeId=8b30159682804, content=<a href='/topic/show?id=bf498e04723' target=_blank style='color:#2F92EE;'>#苯二氮卓类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87047, encryptionId=bf498e04723, topicName=苯二氮卓类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de2518431662, createdName=海豹, createdTime=Tue Oct 16 08:30:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349329, encodeId=aeaa34932945, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4mzqK7XHyH86ToibWNdzamnZozW6yiceXFib4QHq1lCOia34v7bgwXUIH1Rdnoqia2y6ibLX156v1xmicZw/0, createdBy=15891613430, createdName=xuexin53, createdTime=Sun Oct 14 22:19:14 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349291, encodeId=2331349291d3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Oct 14 17:51:58 CST 2018, time=2018-10-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1776634, encodeId=032d1e7663435, content=<a href='/topic/show?id=457f8622190' target=_blank style='color:#2F92EE;'>#自杀风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86221, encryptionId=457f8622190, topicName=自杀风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65df38986519, createdName=Eleven24, createdTime=Fri Aug 09 00:30:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596828, encodeId=8b30159682804, content=<a href='/topic/show?id=bf498e04723' target=_blank style='color:#2F92EE;'>#苯二氮卓类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87047, encryptionId=bf498e04723, topicName=苯二氮卓类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de2518431662, createdName=海豹, createdTime=Tue Oct 16 08:30:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349329, encodeId=aeaa34932945, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4mzqK7XHyH86ToibWNdzamnZozW6yiceXFib4QHq1lCOia34v7bgwXUIH1Rdnoqia2y6ibLX156v1xmicZw/0, createdBy=15891613430, createdName=xuexin53, createdTime=Sun Oct 14 22:19:14 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349291, encodeId=2331349291d3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Oct 14 17:51:58 CST 2018, time=2018-10-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1776634, encodeId=032d1e7663435, content=<a href='/topic/show?id=457f8622190' target=_blank style='color:#2F92EE;'>#自杀风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86221, encryptionId=457f8622190, topicName=自杀风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65df38986519, createdName=Eleven24, createdTime=Fri Aug 09 00:30:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596828, encodeId=8b30159682804, content=<a href='/topic/show?id=bf498e04723' target=_blank style='color:#2F92EE;'>#苯二氮卓类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87047, encryptionId=bf498e04723, topicName=苯二氮卓类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de2518431662, createdName=海豹, createdTime=Tue Oct 16 08:30:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349329, encodeId=aeaa34932945, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4mzqK7XHyH86ToibWNdzamnZozW6yiceXFib4QHq1lCOia34v7bgwXUIH1Rdnoqia2y6ibLX156v1xmicZw/0, createdBy=15891613430, createdName=xuexin53, createdTime=Sun Oct 14 22:19:14 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349291, encodeId=2331349291d3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Oct 14 17:51:58 CST 2018, time=2018-10-14, status=1, ipAttribution=)]
    2018-10-14 xuexin53

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1776634, encodeId=032d1e7663435, content=<a href='/topic/show?id=457f8622190' target=_blank style='color:#2F92EE;'>#自杀风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86221, encryptionId=457f8622190, topicName=自杀风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65df38986519, createdName=Eleven24, createdTime=Fri Aug 09 00:30:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596828, encodeId=8b30159682804, content=<a href='/topic/show?id=bf498e04723' target=_blank style='color:#2F92EE;'>#苯二氮卓类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87047, encryptionId=bf498e04723, topicName=苯二氮卓类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de2518431662, createdName=海豹, createdTime=Tue Oct 16 08:30:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349329, encodeId=aeaa34932945, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4mzqK7XHyH86ToibWNdzamnZozW6yiceXFib4QHq1lCOia34v7bgwXUIH1Rdnoqia2y6ibLX156v1xmicZw/0, createdBy=15891613430, createdName=xuexin53, createdTime=Sun Oct 14 22:19:14 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349291, encodeId=2331349291d3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Oct 14 17:51:58 CST 2018, time=2018-10-14, status=1, ipAttribution=)]
    2018-10-14 医者仁心5538

    学习了

    0

相关资讯

警惕苯二氮卓类与阿片类药物联合应用导致药物过量反应

美国健康官员周三发表了警示,将阿片类止痛剂与一类药物联合应用可能会导致致命的药物过量,这类药物包括常见的镇静剂,如安定和阿普唑仑等。 FDA特派员Robert Calif博士在媒体简报中表示,美国FDA将要求389中不同产品的包装盒上注明警告,以告知医护人员和广大患者这种潜在的致命的药物相互作用。 FDA药物评价与研究中心调整项目副主管Doug Throckmorton博士表示

Int J Geriatr Psych:谨慎使用苯二氮卓类药物,增加41%的AD死亡风险

新研究显示,使用苯二氮卓类及相关药物(BZRDs)的阿尔茨海默病(AD)患者的死亡风险比不使用这些药物的患者高41%。

Pain:联合使用苯二氮卓类与阿片类药物的风险增加!

苯二氮卓类药物和阿片类药物通常用于患有精神疾病和疼痛的退伍军人中。近期,一项发表在杂志Pain上的研究旨在确定相伴使用苯二氮卓类-阿片类增加是否会发生超过非急性阿片类药物使用基线风险的不利结果的发生。此项研究包含了2008年至2012年期间至少需要一项阿片类处方的所有退伍军人。非急性阿片类药物的使用被定义为在60天内具有大于或等于20天的阿片类药物处方。相伴使用被定义为重叠使用至少七天的阿片样物质